| Salmeterol: an inhaled beta 2-agonist with prolonged duration of action. | |
| | |
MedLine Citation:
|
PMID: 8105155 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Salmeterol (Serevent) is an inhaled beta 2-receptor agonist with more than twelve hours' effect duration compared with 4-6 hours for the more short-acting substances bitolterol, fenoterol, salbutamol, and terbutaline. Salmeterol has been studied in several large-scale double-blind multicenter studies with up to one year's duration. More than 6,000 asthmatics have been treated with salmeterol during these controlled studies. All studies show salmeterol to have a significantly better and well-maintained bronchodilating effect with better asthma control, fewer asthma exacerbations, and a decreased need for rescue albuterol inhalations used on demand compared to the treatments in the control groups (200-400 micrograms albuterol q.i.d., inhaled albuterol given only p.r.n., terbutaline given regularly, or individually titrated slow-release theophylline). Salmeterol should be given b.i.d. and in combination with inhaled corticosteroids. Salmeterol seems especially effective in patients with nocturnal symptoms, exercise induced asthma, and in patients sensitive to inhaled irritants such as cold air. The patients should always have short-acting inhaled beta 2-agonists available for break-through attacks. Inhaled salmeterol in combination with inhaled steroids seems to give the best maintenance asthma control available by inhalation today. |
| | |
Authors:
|
J Lötvall; N Svedmyr |
Related Documents
:
|
20584595 - Difference between patient-reported side effects of ciclesonide versus fluticasone prop... 9284985 - A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthm... 15221875 - Corticosteroid use in the treatment of neuromuscular disorders: empirical and evidence-... 15950835 - Assessment of a therapeutic education programme for asthma patients: "un souffle nouveau". 18580345 - Admission microalbuminuria and neurologic outcomes in intensive care unit patients with... 23413135 - A randomized, double-blind, crossover, placebo-controlled comparative clinical trial of... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Lung Volume: 171 ISSN: 0341-2040 ISO Abbreviation: Lung Publication Date: 1993 |
Date Detail:
|
Created Date: 1993-11-23 Completed Date: 1993-11-23 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7701875 Medline TA: Lung Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 249-64 Citation Subset: IM |
Affiliation:
|
Department of Clinical Pharmacology, Shalgrenska University Hospital, Göteborg, Sweden. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Inhalation Adrenergic beta-Agonists / administration & dosage*, adverse effects Albuterol / administration & dosage, adverse effects, analogs & derivatives* Asthma / drug therapy*, physiopathology Bronchial Hyperreactivity / drug therapy, physiopathology Bronchodilator Agents / administration & dosage*, adverse effects Clinical Trials as Topic Humans Lung Volume Measurements Receptors, Adrenergic, beta-2 / drug effects*, physiology |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Agonists; 0/Bronchodilator Agents; 0/Receptors, Adrenergic, beta-2; 18559-94-9/Albuterol; 89365-50-4/salmeterol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Quantitative microdialysis of neurotransmitters.
Next Document: Differentiation of purified malignant B cells induced by PMA or by activated normal T cells.